The use of nonhuman primate models in HIV vaccine developmentSIV infection of rhesus macaques of Chinese origin: a suitable model for HIV infection in humansTracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutininCo-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cellsNew recombinant vaccines based on the use of prokaryotic antigen-display systems.Differentiation of a passive vaccine and the humoral immune response toward infection: analysis of phage displayed peptides.Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccinesVaccine delivery to the oral cavity using coated microneedles induces systemic and mucosal immunityPassive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaquesTransfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNADetermination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodiesSequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodiesHIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans.Functional and Molecular Characteristics of Novel and Conserved Cross-Clade HIV Envelope Specific Human Monoclonal AntibodiesDNA vaccine strategies: candidates for immune modulation and immunization regimens.Immunoprophylaxis to prevent mother-to-child transmission of HIV-1.HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells.Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodiesAnimal models in HIV-1 protection and therapyE2 multimeric scaffold for vaccine formulation: immune response by intranasal delivery and transcriptome profile of E2-pulsed dendritic cellsPre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaquesMutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses.Animal models for perinatal transmission of HIV-1.Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challengeDNA sequence organization of the beta-globin complex in the BALB/c mouse.Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.Transmission of HIV-1 in the face of neutralizing antibodies.High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection.Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaquesNeutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaquesImmune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination.Improvement of antibody responses by HIV envelope DNA and protein co-immunization.Neutralizing antibodies and control of HIV: moves and countermoves.Use of broadly neutralizing antibodies for HIV-1 prevention.
P50
Q21563403-C0D65B42-83C6-449D-A42F-D881253FA80FQ27014903-E51D95E2-6922-4157-A4B1-95B54D9FC3F7Q28264707-06C6A76A-7FE4-45DC-A28F-3C8697BD5B56Q28732043-87F896E3-FAA9-4F3D-926F-756A4C7635ADQ33210092-2963516A-512B-4D0E-9469-E5F6C92F6CFCQ33223593-48EF084D-3145-4438-8229-489BFE0425ACQ33911935-0A05C13A-9696-4579-819F-7D6FED8C1555Q34175719-E7C9CD16-2D44-4A6D-B5A1-9FA60C0A2BA6Q34185625-B15A9B0E-98F0-41B7-9112-7DE65D851AC5Q34301728-E5C1FC61-78A2-4769-B775-A5CE30662A48Q34391256-82684371-8D85-4C08-BEDB-B5236AC508EBQ34522384-B7FC8278-BC2A-4AC6-A035-AF07E416D71AQ34594513-2C4DFFD6-B8E6-4512-9F6F-275534EEE3B0Q34594701-42784867-BC47-4FC7-BEF3-2DA5D02F41E2Q34712503-7E361EC2-A562-40C2-97C8-2266B94A2CCBQ34970873-380E4922-DB37-48BD-A42D-EBEF5C3B4A2FQ34982715-A566D008-94B0-4C5F-B4A8-39397B28DAACQ34990575-E3FE597E-A00B-413A-9097-9186EA956B03Q35540085-21A7ECB1-9F22-48CF-B061-EBAC6F7ADE61Q35544636-A0EA3F6A-0C83-4B26-AD08-FBF95F57EBC1Q35628408-1C983A0C-3E96-425B-87BE-6B1A3ABC5974Q35745815-A7FE5B74-4799-4951-A86F-34B0303A286FQ35857254-9CFF5097-A4E6-4393-833A-1B8540F50059Q35920037-F20B31A5-F2F8-4633-BF85-986C533D0001Q36078930-D156E6FC-8EDE-4CD3-96E9-C138B4BFD68FQ36286484-1EB07182-365A-4BBE-AC83-9E9A1A065A0CQ36315745-0D214C81-AFF6-4ADF-928C-86E7D7AB8458Q36486675-0EA8D5C0-CA86-49BA-A7F5-E4C2F2AE5164Q36538907-9C8918CF-96C8-48EB-9F32-DB954381FD12Q36595063-0A22284A-80D0-4183-995E-85A37ED98FEFQ36702114-E6EB299E-4182-4FE2-8BEA-5BC1ED28160AQ36920319-BC27F19E-AFCE-4AAE-A353-F19E20189F59Q37017806-3418FBD8-306C-49E6-AFDE-E2F4C0360E99Q37127899-CA2B7F0C-909C-4941-8DAB-1B227F64BD68Q37171570-0A731A2E-1827-4EB7-8F48-1CF4BE017A71Q37252831-1591791F-CC64-4EE8-88C5-C28B5FAD842BQ37425515-DAD6C713-1DCD-48EB-9C43-83EA3B3F2C95Q37588371-AF384459-7141-4F66-A591-F784BCCB6A7CQ37971867-96C745B5-C8C0-4D08-B99C-02026C0FA447Q38764543-EDCF8BE0-B4F0-4F61-AE6F-408D3C107D80
P50
description
American scientist
@en
Amerikaans onderzoekster
@nl
científica estadounidense
@es
name
Nancy Haigwood
@ast
Nancy Haigwood
@en
Nancy Haigwood
@es
Nancy Haigwood
@nl
Nancy Haigwood
@sl
type
label
Nancy Haigwood
@ast
Nancy Haigwood
@en
Nancy Haigwood
@es
Nancy Haigwood
@nl
Nancy Haigwood
@sl
altLabel
Nancy L. Haigwood
@en
Nancy L. Haigwood
@es
prefLabel
Nancy Haigwood
@ast
Nancy Haigwood
@en
Nancy Haigwood
@es
Nancy Haigwood
@nl
Nancy Haigwood
@sl
P1006
P214
P244
P269
P1006
P101
P106
P1153
7004754144
P1412
P1960
8RCYAA8AAAAJ
P21
P213
0000 0000 4912 9682
P214
P2381
P244
nr94011719
P269
P31
P496
0000-0002-1477-9575